An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
|Articles|May 11, 2022
Daily Medication Pearl: Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) for Hepatitis C
Author(s)Saro Arakelians, PharmD
Vosevi is a fixed-dose combination for the treatment of hepatitis C virus.
Advertisement
Medication Pearl of the Day: Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir)
Indication: Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) is a fixed-dose combination for the treatment of hepatitis C virus (HCV). It combines 3 drugs that each act by a different mechanism of action against HCV.
Insight:
- Dosing:Recommended dosage 1 tablet (400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir) taken orally once daily with food,
- Dosage forms: Tablets 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.
- Adverse events:The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with Vosevi for 12 weeks were headache, fatigue, diarrhea, and nausea.
- Mechanism of action: Vosevi is a fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir, which are direct-acting agents against HCV.
- Manufacturer: Gilead Pharmaceuticals
Source:
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5